Literature DB >> 35057647

The ring vaccination trial design for the estimation of vaccine efficacy and effectiveness during infectious disease outbreaks.

Natalie E Dean1, Ira M Longini2.   

Abstract

The ring vaccination trial is a recently developed approach for evaluating the efficacy and effectiveness of vaccines, modeled after the surveillance and containment strategy of ring vaccination. Contacts and contacts of contacts of a newly identified disease case form a ring, and these rings are randomized as part of a cluster-randomized trial or with individual randomization within rings. Key advantages of the design include its flexibility to follow the epidemic as it progresses and the targeting of high-risk participants to increase power. We describe the application of the design to estimate the efficacy and effectiveness of an Ebola vaccine during the 2014-2016 West African Ebola epidemic. The design has several notable statistical features. Because vaccination occurs around the time of exposure, the design is particularly sensitive to the choice of per protocol analysis period. If incidence wanes before the per protocol analysis period begins (due to a slow-acting vaccine or a fast-moving pathogen), power can be substantially reduced. Mathematical modeling is valuable for exploring the suitability of the approach in different disease settings. Another statistical feature is zero inflation, which can occur if the chain of transmission does not take off within a ring. In the application to Ebola, the majority of rings had zero subsequent cases. The ring vaccination trial can be extended in several ways, including the definition of rings (e.g. contact-based, spatial, and occupational). The design will be valuable in settings where the spatio-temporal spread of the pathogen is highly focused and unpredictable.

Entities:  

Keywords:  Cluster randomized trial; infectious diseases; per protocol; ring vaccination; vaccines

Mesh:

Substances:

Year:  2022        PMID: 35057647      PMCID: PMC9300768          DOI: 10.1177/17407745211073594

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.599


  23 in total

1.  Intent-to-treat analysis and preventive vaccine efficacy.

Authors:  A D Horne; P A Lachenbruch; K L Goldenthal
Journal:  Vaccine       Date:  2000-09-15       Impact factor: 3.641

2.  Smallpox eradication in West and Central Africa.

Authors:  W H Foege; J D Millar; D A Henderson
Journal:  Bull World Health Organ       Date:  1975       Impact factor: 9.408

3.  Competing Effects of Indirect Protection and Clustering on the Power of Cluster-Randomized Controlled Vaccine Trials.

Authors:  Matt D T Hitchings; Marc Lipsitch; Rui Wang; Steven E Bellan
Journal:  Am J Epidemiol       Date:  2018-08-01       Impact factor: 4.897

Review 4.  Transmissibility and Pathogenicity of Ebola Virus: A Systematic Review and Meta-analysis of Household Secondary Attack Rate and Asymptomatic Infection.

Authors:  Natalie E Dean; M Elizabeth Halloran; Yang Yang; Ira M Longini
Journal:  Clin Infect Dis       Date:  2016-02-29       Impact factor: 9.079

5.  DESIGN OF VACCINE TRIALS DURING OUTBREAKS WITH AND WITHOUT A DELAYED VACCINATION COMPARATOR.

Authors:  Natalie E Dean; M Elizabeth Halloran; Ira M Longini
Journal:  Ann Appl Stat       Date:  2018-03-09       Impact factor: 2.083

6.  Effectiveness of Ring Vaccination as Control Strategy for Ebola Virus Disease.

Authors:  Adam J Kucharski; Rosalind M Eggo; Conall H Watson; Anton Camacho; Sebastian Funk; W John Edmunds
Journal:  Emerg Infect Dis       Date:  2016-01       Impact factor: 6.883

7.  Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).

Authors:  Ana Maria Henao-Restrepo; Anton Camacho; Ira M Longini; Conall H Watson; W John Edmunds; Matthias Egger; Miles W Carroll; Natalie E Dean; Ibrahima Diatta; Moussa Doumbia; Bertrand Draguez; Sophie Duraffour; Godwin Enwere; Rebecca Grais; Stephan Gunther; Pierre-Stéphane Gsell; Stefanie Hossmann; Sara Viksmoen Watle; Mandy Kader Kondé; Sakoba Kéïta; Souleymane Kone; Eewa Kuisma; Myron M Levine; Sema Mandal; Thomas Mauget; Gunnstein Norheim; Ximena Riveros; Aboubacar Soumah; Sven Trelle; Andrea S Vicari; John-Arne Røttingen; Marie-Paule Kieny
Journal:  Lancet       Date:  2016-12-23       Impact factor: 79.321

8.  An online decision tree for vaccine efficacy trial design during infectious disease epidemics: The InterVax-Tool.

Authors:  Steven E Bellan; Rosalind M Eggo; Pierre-Stéphane Gsell; Adam J Kucharski; Natalie E Dean; Richard Donohue; Matt Zook; W John Edmunds; Frank Odhiambo; Ira M Longini; Marc Brisson; Barbara E Mahon; Ana Maria Henao-Restrepo
Journal:  Vaccine       Date:  2019-06-24       Impact factor: 3.641

9.  Challenges of evaluating and modelling vaccination in emerging infectious diseases.

Authors:  Zachary J Madewell; Natalie E Dean; Jesse A Berlin; Paul M Coplan; Kourtney J Davis; Claudio J Struchiner; M Elizabeth Halloran
Journal:  Epidemics       Date:  2021-10-05       Impact factor: 5.324

10.  The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola.

Authors: 
Journal:  BMJ       Date:  2015-07-27
View more
  2 in total

Review 1.  Monkeypox and Its Possible Sexual Transmission: Where Are We Now with Its Evidence?

Authors:  Ranjit Sah; Abdelaziz Abdelaal; Abdullah Reda; Basant E Katamesh; Emery Manirambona; Hanaa Abdelmonem; Rachana Mehta; Ali A Rabaan; Saad Alhumaid; Wadha A Alfouzan; Amer I Alomar; Faryal Khamis; Fadwa S Alofi; Maha H Aljohani; Amal H Alfaraj; Mubarak Alfaresi; Jumana M Al-Jishi; Jameela Alsalman; Ahlam Alynbiawi; Mohammed S Almogbel; Alfonso J Rodriguez-Morales
Journal:  Pathogens       Date:  2022-08-17

2.  An introduction to the Marburg virus vaccine consortium, MARVAC.

Authors:  Robert W Cross; Ira M Longini; Stephan Becker; Karin Bok; David Boucher; Miles W Carroll; Janet V Díaz; William E Dowling; Ruxandra Draghia-Akli; James T Duworko; John M Dye; Michael A Egan; Patricia Fast; Amy Finan; Courtney Finch; Thomas R Fleming; Joan Fusco; Thomas W Geisbert; Anthony Griffiths; Stephan Günther; Lisa E Hensley; Anna Honko; Ruth Hunegnaw; Jocelyn Jakubik; Julie Ledgerwood; Kerstin Luhn; Demetrius Matassov; Jeffrey Meshulam; Emily V Nelson; Christopher L Parks; Roxana Rustomjee; David Safronetz; Lauren M Schwartz; Dean Smith; Paul Smock; Ydrissa Sow; Christina F Spiropoulou; Nancy J Sullivan; Kelly L Warfield; Daniel Wolfe; Courtney Woolsey; Roland Zahn; Ana María Henao-Restrepo; César Muñoz-Fontela; Andrea Marzi
Journal:  PLoS Pathog       Date:  2022-10-13       Impact factor: 7.464

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.